Swiss Re is completing its withdrawal from the IptiQ business.
The reinsurer has reached an agreement to sell the Americas business, subject to regulatory approvals, and will run-off the EMEA life and health business.
The final moves were revealed in the reinsurer’s annual results last month.
“Swiss Re has reached an agreement to sell the IptiQ Americas business, subject to regulatory approvals, and will move the IptiQ EMEA L&H business into run-off,” it said.
“Earlier in 2025, Swiss Re completed the sale of the IptiQ Americas Sales Solutions business through a management buyout, the sale of the IptiQ EMEA P&C business and the sale of IptiQ’s Australian business.
“As such, all parts of the IptiQ business have now either been sold or will be placed into run-off in due course.”
The withdrawal from the platform was originally announced by the reinsurer in May 2024.
“Following a strategic review of its digital white-label platform, Swiss Re plans to withdraw from the iptiQ business and will consider options for the different entities in a manner and timeframe that maximises value for the group, subject to applicable regulatory approvals and notifications,“ it said at the time.
Group chief executive officer Christian Mumenthaler added: “The market environment today is vastly different from the one when IptiQ was created. Given these changed conditions and Swiss Re’s strategic priorities, we’ve concluded we are not the best owners of this business going forward.“
